Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
Guiliang Wang,1,2 Yan Liu,2 Ping Qiu,1 Shu-Feng Zhou,3,4 Linfang Xu,1 Ping Wen,1 Jianbo Wen,1 Xianzhong Xiao5 1Department of Digestive Internal Medicine, Gannan Medical University Pingxiang Hospital, Pingxiang, People’s Republic of China; 2Department of Digestive Internal Medicine, 307 Ho...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-06-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/cost-effectiveness-analysis-of-lamivudine-telbivudine-and-entecavir-in-peer-reviewed-article-DDDT |
| _version_ | 1818609408563740672 |
|---|---|
| author | Wang G Liu Y Qiu P Zhou SF Xu L Wen P Wen J Xiao X |
| author_facet | Wang G Liu Y Qiu P Zhou SF Xu L Wen P Wen J Xiao X |
| author_sort | Wang G |
| collection | DOAJ |
| description | Guiliang Wang,1,2 Yan Liu,2 Ping Qiu,1 Shu-Feng Zhou,3,4 Linfang Xu,1 Ping Wen,1 Jianbo Wen,1 Xianzhong Xiao5 1Department of Digestive Internal Medicine, Gannan Medical University Pingxiang Hospital, Pingxiang, People’s Republic of China; 2Department of Digestive Internal Medicine, 307 Hospital of PLA, Beijing, People’s Republic of China; 3Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA; 4Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guiyang Medical University, Guiyang, People’s Republic of China; 5Laboratory of Shock, Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China Abstract: The purpose of this study was to analyze the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), and entecavir (ETV) in treatment of chronic hepatitis B with adefovir dipivoxil (ADV) resistance. Two hundred and fifty-two patients were recruited and screened for resistance to ADV and randomly assigned into three groups: LMV + ADV, LdT + ADV, and ETV + ADV. The ratio of biochemical response, virological response, seroconversion of hepatitis Be antigen (HBeAg)/hepatitis Be antibody (HBeAb), viral breakthrough, and the cost and effectiveness of treatments were analyzed. A comparison of the results of the ratio of biochemical response, virological response and seroconversion of HBeAg/HBeAb, showed no statistical difference between the three groups, with the economic cost of LMV + ADV the lowest, LdT + ADV the middle, and ETV + ADV the highest. The side effects of the three plans are all rare and tolerable. LMV + ADV is the optimal rescue strategy, and LdT + ADV the alternative selection in the economically less developed regions, while ETV + ADV was used in the economically developed regions. Keywords: chronic hepatitis B, adefovir dipivoxil, lamivudine, telbivudine, entecavir, resistance |
| first_indexed | 2024-12-16T14:58:04Z |
| format | Article |
| id | doaj.art-afd4edd63ecf433b881322312066b5b4 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-16T14:58:04Z |
| publishDate | 2015-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-afd4edd63ecf433b881322312066b5b42022-12-21T22:27:23ZengDove Medical PressDrug Design, Development and Therapy1177-88812015-06-012015default2839284621963Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistanceWang GLiu YQiu PZhou SFXu LWen PWen JXiao XGuiliang Wang,1,2 Yan Liu,2 Ping Qiu,1 Shu-Feng Zhou,3,4 Linfang Xu,1 Ping Wen,1 Jianbo Wen,1 Xianzhong Xiao5 1Department of Digestive Internal Medicine, Gannan Medical University Pingxiang Hospital, Pingxiang, People’s Republic of China; 2Department of Digestive Internal Medicine, 307 Hospital of PLA, Beijing, People’s Republic of China; 3Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA; 4Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guiyang Medical University, Guiyang, People’s Republic of China; 5Laboratory of Shock, Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China Abstract: The purpose of this study was to analyze the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), and entecavir (ETV) in treatment of chronic hepatitis B with adefovir dipivoxil (ADV) resistance. Two hundred and fifty-two patients were recruited and screened for resistance to ADV and randomly assigned into three groups: LMV + ADV, LdT + ADV, and ETV + ADV. The ratio of biochemical response, virological response, seroconversion of hepatitis Be antigen (HBeAg)/hepatitis Be antibody (HBeAb), viral breakthrough, and the cost and effectiveness of treatments were analyzed. A comparison of the results of the ratio of biochemical response, virological response and seroconversion of HBeAg/HBeAb, showed no statistical difference between the three groups, with the economic cost of LMV + ADV the lowest, LdT + ADV the middle, and ETV + ADV the highest. The side effects of the three plans are all rare and tolerable. LMV + ADV is the optimal rescue strategy, and LdT + ADV the alternative selection in the economically less developed regions, while ETV + ADV was used in the economically developed regions. Keywords: chronic hepatitis B, adefovir dipivoxil, lamivudine, telbivudine, entecavir, resistancehttp://www.dovepress.com/cost-effectiveness-analysis-of-lamivudine-telbivudine-and-entecavir-in-peer-reviewed-article-DDDT |
| spellingShingle | Wang G Liu Y Qiu P Zhou SF Xu L Wen P Wen J Xiao X Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance Drug Design, Development and Therapy |
| title | Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance |
| title_full | Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance |
| title_fullStr | Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance |
| title_full_unstemmed | Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance |
| title_short | Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance |
| title_sort | cost effectiveness analysis of lamivudine telbivudine and entecavir in treatment of chronic hepatitis b with adefovir dipivoxil resistance |
| url | http://www.dovepress.com/cost-effectiveness-analysis-of-lamivudine-telbivudine-and-entecavir-in-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT wangg costeffectivenessanalysisoflamivudinetelbivudineandentecavirintreatmentofchronichepatitisbwithadefovirdipivoxilresistance AT liuy costeffectivenessanalysisoflamivudinetelbivudineandentecavirintreatmentofchronichepatitisbwithadefovirdipivoxilresistance AT qiup costeffectivenessanalysisoflamivudinetelbivudineandentecavirintreatmentofchronichepatitisbwithadefovirdipivoxilresistance AT zhousf costeffectivenessanalysisoflamivudinetelbivudineandentecavirintreatmentofchronichepatitisbwithadefovirdipivoxilresistance AT xul costeffectivenessanalysisoflamivudinetelbivudineandentecavirintreatmentofchronichepatitisbwithadefovirdipivoxilresistance AT wenp costeffectivenessanalysisoflamivudinetelbivudineandentecavirintreatmentofchronichepatitisbwithadefovirdipivoxilresistance AT wenj costeffectivenessanalysisoflamivudinetelbivudineandentecavirintreatmentofchronichepatitisbwithadefovirdipivoxilresistance AT xiaox costeffectivenessanalysisoflamivudinetelbivudineandentecavirintreatmentofchronichepatitisbwithadefovirdipivoxilresistance |